|[February 22, 2013]
Global Leaders in Oncology Voice Support for WIN Consortium's 2013 Symposium in Personalized Cancer Medicine
VILLEJUIF, France --(Business Wire)--
The Worldwide Innovative Networking (WIN) Consortium in personalized
cancer medicine is a global network of 28 leading academic, pharma, life
science, and patient advocacy organizations spanning 13 countries.
WIN2013, the 5th in a series of Symposia
dedicated to advancing personalized cancer medicine through global
collaboration, will be held July 10-12, in Paris, France.
The WIN2013 theme, Personalized Cancer Medicine: From Innovation to
Implementation, will bring leaders from around the world together in
a collaborative, global forum to share innovations that represent the
most promising advances in personalized cancer care.
Global leaders in oncology have voiced their support for WIN2013. "I
do not know of another forum which is designed to enable the
globalization of patient specific cancer care; the discussions cover new
technology through to clinical trials" stated Mike Pellini,
CEO of Foundation Medicine. "The forum's perspective is powerful. I
look forward sharing our learnings with one anothr so we can take one
more step in the direction of truly personalized cancer care."
John Mendelsohn, Director, Khalifa Institute for Personalized Cancer
Medicine and Past-President, MD Anderson, noted "The annual WIN
Symposium in Paris provides a unique opportunity for leading
stakeholders from academia, industry, government and advocacy groups in
genomic cancer medicine to present data, exchange ideas and develop new
Patient advocacy leader and breast cancer survivor Janelle Hail, Founder
and CEO of the National Breast Cancer Foundation, noted, "WIN has
become the catalyst for global advancement in personalized cancer care.
With the growing constituency of academia, industry, government, and
genomic cancer medicine advocacy groups collaborating through WIN,
answers will emerge to empower patients to have some part of control
over their own destiny."
Featuring globally recognized experts from academia, life sciences,
pharma, healthcare IT, and patient advocacy, WIN2013 includes plenary
- OMICS Assays That Support Personalized Clinical Care Today
Moderator: Alexander Eggermont, Institut Gustave Roussy
- Analysis and Clinical Application of Genomics
Moderator: Levi Garraway, Dana-Farber Cancer Institute
- Clinical Progress in Personalized Cancer Therapy
Moderator: Richard L. Schilsky, ASCO
- New Approaches That Impact Personalized Cancer Care
Moderator: John Mendelsohn, MD Anderson Cancer Center
Early Registration for WIN2013 ends April 1.
abstract submission, and full scientific program online: www.winsymposium.org
[ Back To Technology News's Homepage ]